You are here: Industry Insights > qiagen

News List

QIAGEN and OncXerna Therapeutics Sign Licensing and Master Companion Diagnostic Agreements firstwordpharma
August 10, 2021
QIAGEN and OncXerna Therapeutics, Inc. today announced signing a master companion diagnostics (CDx) agreement to develop a NGS CDx for OncXerna's product candidate, Navicixizumab, and a non-exclusive license to the Xerna™ TME panel.
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) firstwordpharma
May 26, 2021
QIAGEN N.V. today announced MRTX to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation from treatment with adagrasib, Mirati's investigational
Labcorp, QIAGEN announce companion diagnostic for metastatic breast cancer biospectrumasia
June 11, 2019
Piqray, in combination with fulvestrant, and therascreen PIK3CA PCR mutation analysis assay received approval from the U.S. Food and Drug Administration (FDA) on May 24, 2019.
Labcorp, QIAGEN announce companion diagnostic for metastatic breast cancer biospectrumasia
June 10, 2019
Piqray, in combination with fulvestrant, and therascreen PIK3CA PCR mutation analysis assay received approval from the U.S. Food and Drug Administration (FDA) on May 24, 2019.
Qiagen launches first FGFR-based cancer diagnostic fiercebiotech
April 17, 2019
Alongside Janssen’s accelerated approval of Balversa as the first targeted therapy for metastatic bladder cancer, the FDA also greenlighted Qiagen’s companion diagnostic test to ...
QIAGEN partners with Ares Genetics to advance global fight against antibiotic-resistant pathogens pharmafocusasia
February 20, 2019
QIAGEN N.V. today announced a broad agreement with Ares Genetics, a subsidiary of Curetis N.V., to develop innovative bioinformatics and assay solutions to ....
QIAGEN and NeoGenomics collaborate to offer cancer patients Day-One access to innovative companion diagnostics for newly approved drugs pharmafocusasia
December 03, 2018
QIAGEN N.V. and NeoGenomics, Inc. today announced a master service agreement to accelerate the availability of innovativ
QIAGEN announces first installation of GeneReader next-generation sequencer in Malaysia prnasia
September 28, 2017
QIAGEN Biotechnology Malaysia Sdn Bhd today announced that it has installed the company's first GeneReader Next-Generation Sequencing (NGS) System in Malaysia.
QIAGEN's QuantiFERON-TB Gold Plus gains U.S. FDA approval biospectrumasia
June 15, 2017
Fourth generation Latent TB blood test combines breakthrough CD4/CD8 design for comprehensive immune response detection with the most flexible blood collection workflow